The company held the 7th meeting of the 11th board of directors and the 7th meeting of the 10th board of supervisors to review and approve the annual work report and other related proposals
Release time:
2022-05-05
News from our newspaper # February 16 , Chairman Jiang Xiaomeng of the Group Company presided over the meeting of the 11th Board of Directors of the Company, it reviewed and approved 17 related reports and proposals such as 2021 annual board of directors report, 2021 annual general manager business report, 2021 annual report, 2021 annual financial final accounts report, 2021 annual profit distribution plan, etc.
General Manager's report pointed out that 2021 is the first year of the national "14th Five-Year Plan" , The management team, according to the company's five-year development plan and the annual management plan approved by the board of directors, focuses on the general working policy of "following the rules, keeping the right and bringing forth new ideas, reforming and innovating, and continuously improving, calmly deal with the new coronary pneumonia epidemic, raw material prices ups and downs, production restrictions and power restrictions and many other challenges, better to complete the work objectives set at the beginning of the year. As of the end of 2021 , the company's total assets were 70.24 .9 billion yuan, up 10.74% year-on-year, and the net assets attributable to shareholders of listed companies were 52.07 .3 billion yuan, up 17.39% year-on-year. For the whole year, operating income reached 38.05 .7 billion yuan, up 17.17% year-on-year, net profit attributable to shareholders reached 9.24 .1 billion yuan, up 58.12% year-on-year, and operating performance reached the best level in history.
2021, the company's cement plate industry chain extension war made new progress, holding the establishment of Hubei peak new building materials Co., Ltd., orderly promote the mechanism of sand project. Actively participated in the major asset restructuring of Tianshan shares and achieved good investment returns. All cement enterprises under the company continue to implement benchmarking management and fine management, carry out in-depth "three reductions and three improvements" activities, steadily implement various technological transformation work, strictly control production costs, and continuously improve the operation efficiency of enterprises. A total of cement clinker ,675 tons were sold throughout the year, up 28% year on year. Daye Peak manages the procurement of raw materials through multi-channel, open and transparent, and full supervision, and strictly controls the procurement cost while ensuring the quality. Continuously optimize the batching scheme, complete the technical transformation of the automatic batching system, increase the proportion of limestone in raw materials, and reduce the cost of raw materials; Continuously optimize the process parameters and use the MES system to trace the optimal parameters, combined with the implementation of more than ten technical transformations such as low-nitrogen combustion at the kiln end and dust collection system at the kiln end, the stability of the equipment has been improved, the overall production capacity of the kiln system has been improved, and the annual cement output has reached the best level in history. Yunnan Jianfeng strictly controls the procurement cost of raw materials by strengthening bidding management. Through the technical renovation of grate cooler, preheater and other equipment, the output of rotary kiln has been effectively increased. Affected by the completion of some key projects in the region and the commissioning of new cement production capacity, the competition in the cement market in this region has intensified and the price has dropped greatly. Therefore, the company further strengthened the regional market segmentation work according to market changes in time and formulated differentiated marketing strategies for different market segments, basically maintain the balance of production and sales. 2021 is the first complete year after Guizhou Jianfeng was put into production. Guizhou Jianfeng relies on the advanced second-generation new dry-process cement production line and adopts digital intelligent control technology to realize all-round intelligent management such as safe production, product quality, material consumption and energy consumption. Strengthen operator training, improve skill level, timely adjust and optimize process parameters, and ensure product quality stability; The whole line has reached the standard and reached the production capacity, coal consumption, electricity consumption, operation rate, kiln production, labor productivity and other indicators reached a good level.
2021, the company made progress in a number of technological innovations and engineering constructions in the pharmaceutical sector. The construction of the annual production of 20 .9 billion solid preparations (internationalization) project in Jinxi Production Base of Jianfeng Pharmaceutical Co., Ltd. is progressing in an orderly manner. At present, the civil engineering and equipment installation and commissioning of the project have been basically completed, and the preliminary preparations for project acceptance and application for certification of cGMP are underway; new North Card and Peak North Card continue to implement comprehensive technological transformation, and intend to upgrade on the basis of existing pesticides and pharmaceutical intermediates, build a comprehensive research and development and production base for APIs, pharmaceutical intermediates and pesticides, and actively promote the industrial upgrading strategy of the integration of APIs and preparations in the pharmaceutical sector of the company. Jianfeng Pharmaceutical and its subsidiaries further increased their investment in research and development and completed the registration of moxifloxacin hydrochloride eye drops, lenvatinib mesylate capsules, valsartan amlodipine tablets and esomeprazole magnesium enteric-coated dry suspension 4 drugs. Peak pharmaceutical products won the bid for the first time in the national drug centralized procurement, olopatadine hydrochloride eye drops won the bid for the fourth batch of national drug centralized procurement, which is conducive to the market promotion of the product, sales have been greatly improved.
In addition, Jianfeng Health has completed the research and development of health food such as coenzyme Q10 soft capsule and broken ganoderma lucidum spore powder, and has obtained the record. Completed the development of many functional foods such as vitality V5 liquid drink and collagen liquid drink, and has now listed 6 ; "Development and Industrialization of Wall-broken Ganoderma lucidum Spore Powder for Enhancing Immunity" was approved by Jinhua Municipal Technology Innovation Project in 2021 . "Cranberry Extract" won the project of key high-tech products in Zhejiang Province in 2021 . Peak cable carried out the subway communication cable "Zhejiang manufacturing" standard construction work, high-speed data transmission with twisted pair communication cable through the "Zhejiang manufacturing" certification, won the representative of Zhejiang manufacturing benchmark "word mark". According to the development trend of regional trade and logistics, combined with the characteristics of the enterprise itself, Jianfeng International Trade has continuously improved its business development model and promoted the development of modern warehousing logistics, commodity supply chain and network freight platform business in an orderly manner. On the day of
, the company also held the st meeting of the 10th board of supervisors, deliberating and passing related reports and proposals such as the company's 2021 annual board of supervisors report. (remaining fruit)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31